XML 92 R75.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail) £ in Millions, $ in Millions | 1 Months Ended |  |
--- | --- | --- | ---
Oct. 31, 2017 USD ($) | Apr. 30, 2017 | Mar. 31, 2015 Patents | Mar. 31, 2013 lagoon | Oct. 01, 2017 Claim | Dec. 31, 2016 GBP (£)
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Number of patents |  |  | 6 |  |  |
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Claims dismissed |  |  | 4 |  |  |
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Number of patents |  |  | 2 |  |  |
Xtandi [Member] | Regents Versus Medivation [Member] | Settled Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Percentage of payments Medivation received sought by Regents |  | 10.00% |  |  |  |
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Number of pending claims | Claim |  |  |  |  | 56,500 |
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Number of pending claims | Claim |  |  |  |  | 1 |
Environmental Remediation Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Number of lagoons | lagoon |  |  |  | 2 |  |
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Imposed fine | £ |  |  |  |  |  | £ 84.2
Subsequent Event [Member] | Celebrex [Member] | Pending Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Amount awarded to other party | $ | $ 94 |  |  |  |  |

X
- Definition Feasibility Study, Number Of Lagoons + References No definition available. + Details
Name: | pfe_FeasibilityStudyNumberOfLagoons
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Collaboration Arrangement, Percentage of Payments Sought by Plaintiff + References No definition available. + Details
Name: | pfe_LossContingencyCollaborationArrangementPercentageofPaymentsSoughtbyPlaintiff
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of claims dismissed. + References No definition available. + Details
Name: | us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of pending claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_InflectraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XtandiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_RegentsVersusMedivationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_ClassActionVersusAmericanOpticalCorporationAndVariousOtherDefendantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_AverageWholesalePriceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_StateofIllinoisVersusPfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_PhenytoinSodiumCapsulesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_CelebrexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |